The PLA academy of military medical academy of military sciences, suzhou abon technology co., LTD and yunnan Watson (300142) biological technology co., LTD., joint research and development will be coronavirusmRNA genetic engineering vaccine, on June 25, start Ⅰ period in tree orchid (hangzhou) hospital clinical trials.
This is also the first novel coronavirusmRNA vaccine approved for clinical trial in China.
MRNA vaccine is a new form of vaccine in recent years. Its basic principle is to introduce the mRNA expressing antigen target into the body through a specific delivery system, express proteins in the body and stimulate the body to produce specific immunological response, so that the vaccinator can obtain immune protection.
Because it turns the human body into a processing plant for its own drugs, revolutionizing the way vaccines are made.
Due to the high technical threshold of mRNA vaccine, only a few mRNA vaccine varieties developed in the United States and Germany have entered the clinical trial stage, and China has never approved mRNA vaccine to enter the clinical trial before.
The first clinical approval of COVID-19 mRNA vaccine was approved and entered into clinical trials, achieving the breakthrough of “zero” mRNA vaccine in China, indicating that China’s mRNA vaccine research and development level and regulatory capacity have been among the forefront of the world.
Domestic NCP mRNA vaccine has three advantages: more accurate selection of vaccine antigen target, high specificity of induced neutralization antibody, and better safety of vaccine;
All the core raw materials and equipment have been localized, and the production capacity can be rapidly enlarged.
It can be stored at room temperature for a week or for a long time at 4℃. The cold chain cost is low and it is easy to achieve mass vaccination.